VG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10
May 01 2014 - 10:22AM
VG Life Sciences (VGLS) is a publically traded biotechnology
company focused on developing treatments for patients suffering
from autoimmune and infectious diseases. VG Life Sciences is
pleased to announce the completion of prior year audits. KWCO, PC
Certified Public Accountants completed the audit, which includes
consolidated balance sheets of the Company as of December 31, 2012
and 2013. It also includes related consolidated statements of
operations, stockholders' equity and yearly cash flows from the
Company's inception in 1995 through the end of 2013. VG Life
Sciences' audited financials will be filed with the Securities
& Exchange Commission as the Company now moves to file Form 10
with the SEC. The Company has engaged Trombly Business Law, PC for
the specific purpose of filing on behalf of the Company. When
approved by the SEC, the Company intends to list on the OTCQB. "We
continue to move through the milestones we committed to in our July
2013 Letter to Shareholders," said John Tynan, President & CEO.
"Restoring financial accountability to the market and our
shareholders is an important step in moving our custom and patented
Targeted Peptide Technology (VG1177) toward clinical trials. VG1177
has a wide range of potential inflammatory and autoimmune
applications, including HIV/AIDS, Hypertension, Preeclampsia, Brain
Trauma, Lyme disease, and many more. So it is important for us to
stay focused and move this breakthrough molecule to market."
Currently the company is in preclinical animal safety studies at
ITR Laboratories in Canada which will conclude in the 4th quarter
of this year. In addition, VG1177 research models are underway at
Texas A &M and other leading research institutions across the
country. The Company is also in a Phase I Physician's IND cancer
clinical trial at the University of Texas.
About VG Life
Sciences Inc. Santa Barbara, California-based VG Life
Sciences, Inc., formerly known as Viral Genetics, is a
biotechnology company focused on discovering and developing drug
therapies for cancer, infectious disease, and inflammatory,
autoimmune disorders. VGLS controls over 45 US and international
patents and pending patents protecting its exclusive biotech
platform technologies. For more information and upcoming events,
visit www.vglifesciences.com or find VG Life Sciences, Inc. on
Facebook, Twitter, and LinkedIn.
Safe Harbor Statement and
Forward-Looking Statements This news release may contain
forward-looking statements that involve risks and uncertainties
associated with financial projections, milestone timelines,
clinical development, regulatory approvals and other risks
described by VG Life Sciences from time to time in its periodic
reports. None of VG Life Sciences' drug compounds are approved by
the US FDA or by any comparable regulatory agencies elsewhere in
the world. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to
be accurate. In light of the significant uncertainties inherent in
the forward-looking statements included herein, the forward-looking
statements should not be regarded as a representation by VG Life
Sciences Inc. or any other person that the objectives and plans of
VG Life Sciences will be achieved.
CONTACT: Allie Trabucco, Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 879-9000
Email: atrabucco@vglifesciences.com
VG Life Sciences (PK) (USOTC:VGLS)
Historical Stock Chart
From Jul 2024 to Aug 2024
VG Life Sciences (PK) (USOTC:VGLS)
Historical Stock Chart
From Aug 2023 to Aug 2024